Chan Philip A, Tashima Karen, Cartwright Charles P, Gillani Fizza S, Mintz Orli, Zeller Kimberly, Kantor Rami
Division of Infectious Disease, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
AIDS Res Hum Retroviruses. 2011 Mar;27(3):275-81. doi: 10.1089/aid.2010.0198. Epub 2010 Oct 18.
Transmission of HIV-1 drug resistance has important clinical and epidemiological consequences including earlier treatment failure and forward transmission of resistance strains in high-risk groups. To evaluate the prevalence and molecular epidemiology of transmitted drug resistance in Rhode Island, we collected genotypic, demographic, clinical, and laboratory data from treatment-naive individuals presenting to the largest outpatient HIV clinic in the state from January 2007 to November 2007. Sequences from 35 treatment-naive individuals were available, 83% of whom were men who had sex with men (MSM). All sequences were HIV-1 subtype B. Drug resistance mutations were identified in 7/35 [20%; 95% confidence interval (CI), 0.08-0.37] patients, six of whom had K103N. Two phylogenetic transmission clusters were found, involving 17% (6/35) of individuals, three in each cluster. We did not find an association between belonging to a cluster and age, gender, AIDS-defining illness, CD4 cell count, or viral load. Drug resistance mutations were more commonly observed in transmission clusters (p = 0.08). Individuals in one cluster all had K103N and were MSM who had attended local bathhouses. Individuals forming clusters were significantly more likely to have visited a bathhouse compared to nonclusters (p = 0.02). The prevalence of transmitted drug resistance in Rhode Island is high, further justifying genotypic testing on presentation to care and prior to treatment initiation. Molecular epidemiological analysis and association of resistance with phylogenetic networks using data obtained for clinical purposes may serve as useful tools for the prevention of drug resistance transmission and for contact tracing.
HIV-1耐药性的传播具有重要的临床和流行病学后果,包括治疗失败提前以及耐药菌株在高危人群中的进一步传播。为评估罗德岛州传播性耐药的流行情况和分子流行病学,我们收集了2007年1月至2007年11月期间到该州最大的门诊HIV诊所就诊的初治个体的基因、人口统计学、临床和实验室数据。获得了35名初治个体的序列,其中83%为男男性行为者(MSM)。所有序列均为HIV-1 B亚型。在7/35 [20%;95%置信区间(CI),0.08 - 0.37] 名患者中鉴定出耐药突变,其中6人有K103N突变。发现了两个系统发育传播簇,涉及17%(6/35)的个体,每个簇中有3人。我们未发现属于某个簇与年龄、性别、艾滋病定义疾病、CD4细胞计数或病毒载量之间存在关联。耐药突变在传播簇中更常见(p = 0.08)。一个簇中的个体均有K103N突变,且都是去过当地澡堂的男男性行为者。与非簇个体相比,形成簇的个体去过澡堂的可能性显著更高(p = 0.02)。罗德岛州传播性耐药的流行率较高,这进一步证明了在就诊时和开始治疗前进行基因检测的合理性。利用为临床目的获得的数据进行分子流行病学分析以及耐药性与系统发育网络的关联分析,可能是预防耐药性传播和进行接触者追踪的有用工具。